XML 49 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segment Information
 9 Months Ended
Oct. 01, 2016
Segment Reporting [Abstract]  
Segment reporting disclosure [Text Block]
SEGMENT INFORMATION

Our reporting segments are as follows:

•
CHC is focused primarily on the global sale of OTC store brand products including cough, cold, allergy and sinus, analgesic, gastrointestinal, smoking cessation, infant formula and food, animal health, and diagnostic products.

•
BCH develops, manufactures, markets and distributes many well-known European OTC brands in the natural health and vitamins, cough, cold and allergy, smoking cessation, personal care and derma-therapeutics, lifestyle, and anti-parasite categories.

•
Rx develops, manufactures and markets a portfolio of generic and specialty pharmaceutical prescription drugs primarily for the U.S. and U.K. markets.

•
Specialty Sciences is comprised primarily of royalties received from assets focused on the management of multiple sclerosis (Tysabri®).

We also have an Other reporting segment that consists of our API business, which does not meet the quantitative threshold required to be a separately reportable segment. Our segments reflect the way in which our chief operating decision maker reviews our operating results and allocates resources.

The below tables show select financial measures by reporting segment (in millions):
Total Assets
 
October 1,
2016
 
December 31, 2015
CHC
 
$
3,873.8

 
$
4,007.8

BCH
 
4,460.2

 
6,324.0

Rx
 
3,304.0

 
3,015.5

Specialty Sciences
 
5,634.0

 
5,833.5

Other
 
195.6

 
213.1

Total
 
$
17,467.6

 
$
19,393.9

 
Three Months Ended
 
October 1, 2016
 
September 26, 2015
 
Net Sales
 
Operating Income (Loss)
 
Intangible Asset Amortization
 
Net Sales
 
Operating Income (Loss)
 
Intangible Asset Amortization
CHC
$
669.1

 
$
100.1

 
$
19.2

 
$
675.2

 
$
117.3

 
$
19.4

BCH
304.0

 
(1,684.3
)
 
38.9

 
302.2

 
4.4

 
36.3

Rx
267.4

 
77.9

 
30.7

 
260.3

 
91.0

 
18.6

Specialty Sciences
93.4

 
23.3

 
72.8

 
84.5

 
9.0

 
72.8

Other
21.0

 
(1.6
)
 
0.5

 
22.5

 
6.2

 
0.5

Unallocated
—

 
(30.6
)
 
—

 
—

 
(39.3
)
 
—

Total
$
1,354.9

 
$
(1,515.2
)
 
$
162.1

 
$
1,344.7

 
$
188.6

 
$
147.6


 
Nine Months Ended
 
October 1, 2016
 
September 26, 2015
 
Net Sales
 
Operating Income (Loss)
 
Intangible Asset Amortization
 
Net Sales
 
Operating Income (Loss)
 
Intangible Asset Amortization
CHC
$
2,055.6

 
$
313.6

 
$
58.1

 
$
2,106.4

 
$
364.8

 
$
52.1

BCH*
1,015.3

 
(2,128.7
)
 
113.9

 
703.4

 
31.0

 
70.5

Rx
817.4

 
262.1

 
90.1

 
790.1

 
290.4

 
55.5

Specialty Sciences
271.3

 
49.7

 
218.3

 
250.1

 
21.0

 
218.4

Other
59.5

 
2.6

 
1.4

 
75.4

 
18.6

 
1.4

Unallocated
—

 
(80.0
)
 
—

 
—

 
(111.1
)
 
—

Total*
$
4,219.1

 
$
(1,580.7
)
 
$
481.8

 
$
3,925.4

 
$
614.7

 
$
397.9


*
The BCH segment was created on March 30, 2015 as a result of the Omega acquisition, thus data for the nine months ended September 26, 2015 includes only six months of results from operations attributable to Omega.